Latest news and press releases about Immix Biopharma, Inc. (IMMX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Price
| Price | $11.92 |
| Market Cap | $648M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.29 |
| EV / EBITDA | -13.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.44% |
| Return on Invested Capital | -18.19% |
| Return on Assets | -16.69% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATOS · COYA · MGNX · ONCY · ORMP · PLRX · SRZN
Explore sector: Healthcare · Biotechnology
More sections of IMMX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks